Tufts: New Neglected Diseases Drug Approvals has Nearly Doubled

mia.burns Number of Annual New Drug Approvals to Treat Neglected Diseases Has Nearly Doubled Between the Early-2000s and 2009-12, According to the Tufts Center for the Study of Drug ...

BioCryst’s failed flu drug gets another shot at FDA success

John Carroll Last fall BioCryst ($ BCRX) took a careful look at the interim data from a late-stage study of its flu drug peramivir i.v. and prepared to read the last rites for the ...

Booming China poised to take a top position in global drug R&D

John Carroll China has invested a total of more than $ 160 billion in building its biotech industry, according to a new assessment from Lux Research. And with 15 clusters–including ...

Accenture Enhances Drug Development

barbara.lempert Accenture Enhances Drug Development from Discovery to Approval with Launch of Accenture Accelerated R&D Services   Company investing more than $ 200 million ...

GSK Survey: Side Effects Limit Prescription Drug Compliance

barbara.lempert GSK Survey Shows Americans Seek More Information from Pharmacists on Medication Side Effects PITTSBURGH, July 10, 2013 /PRNewswire/ — While prescription ...

NYT: Amgen, Sanofi, Pfizer scramble to take lead in hot PCSK9 drug race

John Carroll One of the hottest competitions in drug development has spurred Amgen, Sanofi and Pfizer to invest heavily in PCSK9 drug programs aimed at lowering bad cholesterol in a ...

Array inks $434M licensing deal on cancer drug program

John Carroll A New York-based biotech startup funded by Aisling Capital has stepped up to partner with Array BioPharma on a preclinical cancer program. Loxo Oncology will fund the preclinical ...

Roche Scuttles Diabetes Drug After Clinical Trial Flops

esilverman In a setback to Roche, the drugmaker has ended a Phase III trial of a high-profile diabetes compound after a data and safety monitoring board determined there were ...

Roche scraps diabetes drug as pRED racks up another PhIII fiasco

John Carroll Once again, Roche's pRED group has a big Phase III snafu to answer for. The Basel-based R&D side of the pharma giant–distinct from the gRED operations at ...

Health Canada Provides Direction to Bioniche Life Sciences Inc. Regarding New Drug Submission Filing

barbara.lempert BELLEVILLE, ON, July 8, 2013 /CNW/ – Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, ...

Mylan’s $1.6B Agila buyout hits snag in India amid cancer drug worries

Tracy Staton Mylan agreed to pay $ 1.6 billion for Agila Specialties, the injectables unit of Strides Arcolab. But Indian regulators are said to be skeptical of the deal, worried about ...

Oncology Drug Labels Need Patient Outcome Data: Basch Explains

esilverman Despite various efforts by the FDA to include patient-reported outcome data in product labeling, this sort of information is lacking, especially for cancer treatments. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS